Previous close | 1.090 |
Open | 1.090 |
Bid | 1.060 x 0 |
Ask | 1.100 x 0 |
Day's range | 1.010 - 1.130 |
52-week range | 0.800 - 3.270 |
Volume | |
Avg. volume | 2,632,715 |
Market cap | 1.403B |
Beta (5Y monthly) | 0.16 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.310 |
Earnings date | 27 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.59 |
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2023 annual results and recent business updates.
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for unresectabl
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, and Servier, a global independent pharmaceutical group, today announced an agreement whereby Servier acquires from CStone the exclusive rights to develop and commercialize TIBSOVO® (ivosidenib tablets) in Greater China and Singapore.